Gloomy Neuroscience Partnering Outlook May Soon Brighten
Executive Summary
At least two companies in the neuroscience space are set to deliver potentially good news by year’s end, with other promising candidates in the offing, according to industry consultant Harry Tracy, who compiled a list of the top 10 partnering opportunities in the field for the upcoming Therapeutic Area Partnerships meeting.
You may also be interested in...
Supernus Set To Launch Trokendi XR Against Generic Topamax
The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.
Mad Scientists And Skunkworks Could Bring Back CNS Creativity, TAP Panelists Say
“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.
J&J’s New Innovation Centers Test Immersion Theory Of Access
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?